Risk of thromboembolic diseases in men with prostate cancer: Results from the population-based PCBaSe Sweden

The Lancet Oncology

Volumn 11, Issue 5, 2010, Pages 450-458

  Van Hemelrijck, Mieke ^a   Adolfsson, Jan ^b   Garmo, Hans ^a,c   Bill Axelson, Anna ^b,c   Bratt, Ola ^d   Ingelsson, Erik ^b   Lambe, Mats ^b,c   Stattin, Pär ^e   Holmberg, Lars ^a,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST;

AGE DISTRIBUTION; AGED; ARTERY EMBOLISM; ARTICLE; CANCER EPIDEMIOLOGY; CANCER STAGING; DEEP VEIN THROMBOSIS; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; SWEDEN; THROMBOEMBOLISM; COHORT ANALYSIS; FOLLOW UP; MIDDLE AGED; PROSTATE TUMOR; REGISTER;

AGED; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; REGISTRIES; RISK FACTORS; SWEDEN; THROMBOEMBOLISM;

EID: 77952305940     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70038-3     Document Type: Article

References (42)

1. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000, 160:809-815.
2. Noldus J, Huland H Early complications of radical prostatectomy. Pelvic vein compression caused by wound drainage. Urologe A 1994, 33:172-174.
3. Heidrich H, Konau E, Hesse P Asymptomatic venous thrombosis in cancer patients-a problem often overlooked. Results of a retrospective and prospective study. Vasa 2009, 38:160-166.
4. Klevecka V, Burmester L, Musch M, Roggenbuck U, Kroepfl D Intraoperative and early postoperative complications of radical retropubic prostatectomy. Urol Int 2007, 79:217-225.
5. Scarpa RM, Carrieri G, Gussoni G, et al. Clinically overt venous thromboembolism after urologic cancer surgery: results from the @RISTOS Study. Eur Urol 2007, 51:130-135.
6. White RH, Keenan CR Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res 2009, 123:S11-S17.
7. Seaman HE, Langley SE, Farmer RD, de Vries CS Venous thromboembolism and cyproterone acetate in men with prostate cancer: a study using the General Practice Research Database. BJU Int 2007, 99:1398-1403.
8. Varenhorst E, Risberg B Effects of estrogen, orchidectomy, and cyproterone acetate on tissue fibrinolysis in patients with carcinoma of the prostate. Invest Urol 1981, 18:355-357.
9. Varenhorst E, Wallentin L, Risberg B The effects of orchiectomy, oestrogens and cyproterone-acetate on the antithrombin-III concentration in carcinoma of the prostate. Urol Res 1981, 9:25-28.
10. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007, 110:1493-1500.
11. Jones RD, Nettleship JE, Kapoor D, Jones HT, Channer KS Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am J Cardiovasc Drugs 2005, 5:141-154.
12. Sajjad Y, Quenby S, Nickson P, Lewis-Jones DI, Vince G Androgen receptors are expressed in a variety of human fetal extragenital tissues: an immunohistochemical study. Asian J Androl 2007, 9:751-759.
13. Schock HW, Herbert Z, Sigusch H, Figulla HR, Jirikowski GF, Lotze U Expression of androgen-binding protein (ABP) in human cardiac myocytes. Horm Metab Res 2006, 38:225-229.
14. Klapcinska B, Jagsz S, Sadowska-Krepa E, Gorski J, Kempa K, Langfort J Effects of castration and testosterone replacement on the antioxidant defense system in rat left ventricle. J Physiol Sci 2008, 58:173-177.
15. Golden KL, Marsh JD, Jiang Y, Moulden J Acute actions of testosterone on contractile function of isolated rat ventricular myocytes. Eur J Endocrinol 2005, 152:479-483.
16. Li S, Li X, Li J, Deng X, Li Y, Cong Y Experimental arterial thrombosis regulated by androgen and its receptor via modulation of platelet activation. Thromb Res 2007, 121:127-134.
17. Huggins C, Hodges CV Studies on prostatic cancer I: The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972, 22:232-240.
18. Damber JE, Aus G Prostate cancer. Lancet 2008, 371:1710-1721.
19. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005, 103:1615-1624.
20. Stattin P, Holmberg E, Bratt O, Adolfsson J, Johansson JE, Hugosson J Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden. J Urol 2008, 180:2423-2429.
21. Barlow L, Westergren K, Holmberg L, Talback M The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 2009, 48:27-33.
22. Adolfsson J, Garmo H, Varenhorst E, et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007, 41:456-477.
23. Statistics in the areas of health and medical care 2007 The National Board of Health and Welfare, (accessed Dec 7, 2009). http://www.scb.se/Pages/SubjectArea____6653.aspx.
24. Statistics Sweden 2008 Central Bureau for Statistics, (accessed Dec 7, 2009). http://www.ssd.scb.se/databaser/makro/MainTable.asp?yp=tansss&xu=C9233001&omradekod=BE&omradetext=Population&lang=2&langdb=1.
25. Hammar N, Alfredsson L, Rosen M, Spetz CL, Kahan T, Ysberg AS A national record linkage to study acute myocardial infarction incidence and case fatality in Sweden. Int J Epidemiol 2001, 30:S30-S34.
26. Ingelsson E, Arnlov J, Sundstrom J, Lind L The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail 2005, 7:787-791.
27. Lindblad U, Rastam L, Ranstam J, Peterson M Validity of register data on acute myocardial infarction and acute stroke: the Skaraborg Hypertension Project. Scand J Soc Med 1993, 21:3-9.
28. Hagel E, Garmo H, Bill-Axelson A, et al. PCBaSe Sweden: a register-based resource for prostate cancer research. Scand J Urol Nephrol 2009, 43:342-349.
29. Oefelein MG, Brant M, Crotty K Idiopathic thromboembolism as the presenting sign of occult prostate cancer. Urology 1998, 51:775-780.
30. Breslow N, Day N Statistical methods in cancer research. Volume II-The design and analysis of cohort studies. IARC Sci Publ 1987, 82:406.
31. Zar N, Garmo H, Holmberg L, Hellman P Risk of second primary malignancies and causes of death in patients with adenocarcinoma and carcinoid of the small intestine. Eur J Cancer 2008, 44:718-725.
32. Jones ME, Swerdlow AJ Bias in the standardized mortality ratio when using general population rates to estimate expected number of deaths. Am J Epidemiol 1998, 148:1012-1017.
33. Engholm G, Ferlay J, Christensen N, et al. NORDCAN: cancer incidence, mortality and prevalence in the Nordic countries, version 3.3: Association of Nordic Cancer Registries. Danish Cancer Society 2008 (accessed Dec 7, 2009). http://www-dep.iarc.fr/NORDCAN/english/frame.asp.
34. Stattin P, Holmberg E, Johansson J, Holmberg L, Adolfsson J, Hugosson J. Outcomes for men with localized prostate cancer in the National Prostate Cancer Register (NPCR) of Sweden. J Natl Cancer Inst (in press).
35. Secin FP, Jiborn T, Bjartell AS, et al. Multi-institutional study of symptomatic deep venous thrombosis and pulmonary embolism in prostate cancer patients undergoing laparoscopic or robot-assisted laparoscopic radical prostatectomy. Eur Urol 2008, 53:134-145.
36. Lee AY, Levine MN Venous thromboembolism and cancer: risks and outcomes. Circulation 2003, 107:I17-I21.
37. Babiker AA, Ekdahl KN, Nilsson B, Ronquist G Prothrombotic effects of prostasomes isolated from prostatic cancer cell lines and seminal plasma. Semin Thromb Hemost 2007, 33:80-86.
38. Toorians AW, Thomassen MC, Zweegman S, et al. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J Clin Endocrinol Metab 2003, 88:5723-5729.
39. Winkler UH Effects of androgens on haemostasis. Maturitas 1996, 24:147-155.
40. Heidenreich A, Pfister D, Ohlmann CH, Engelmann UH Androgen deprivation for advanced prostate cancer. Urologe A 2008, 47:270-283.
41. Miettinen OS The need for randomization in the study of intended effects. Stat Med 1983, 2:267-271.
42. Giovannucci E, Rimm EB, Ascherio A, et al. Smoking and risk of total and fatal prostate cancer in United States health professionals. Cancer Epidemiol Biomarkers Prev 1999, 8:277-282.